Overall market sentiment has been high on Mersana Therapeutics Inc (MRSN) stock lately. MRSN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Mersana Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MRSN!
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With MRSN Stock Today?
Mersana Therapeutics Inc (MRSN) stock is flat 0% while the S&P 500 has fallen -0.01% as of 4:00 PM on Wednesday, Nov 29. MRSN is unchanged $0.00 from the previous closing price of $1.59 on volume of 200,291 shares. Over the past year the S&P 500 is higher by 14.97% while MRSN has fallen -75.98%. MRSN lost -$1.78 per share in the over the last 12 months.
To screen for more stocks like Mersana Therapeutics Inc click here.
More About Mersana Therapeutics Inc
Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.
Click Here to get the full Stock Report for Mersana Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
